The Third Circuit recently vacated and remanded a district court’s decision granting class certification for a class of third-party payors (“TPPs”) pursuing Racketeer Influenced and Corrupt Organizations Act (“RICO”) claims against GlaxoSmithKline LLC (“GSK”). See In re Avandia Mktg., Sales Pracs. & Prod. Liab. Litig., 2026 WL 2093904 (3d Cir. July 21, 2026). The TPPs’ claims are based on GSK allegedly misrepresenting Avandia’s cardiovascular risks and benefits.
The central issue on appeal was whether the class of TPPs satisfied Rule 23’s requirements for class certification.
Continue Reading Third Circuit Raises the Bar for Proving Causation Through Statistical Evidence in RICO Pharmaceutical Fraud Class Actions